Dr. Selwyn Ho
Dr. Selwyn Ho has over 25 years of international experience across Europe, US, and Asia in executive and senior management positions in both privately held and publicly traded biotech and pharma companies with a focus on inflammation and immunology, with various responsibilities in the areas of Product Development, Medical Affairs, Strategic Marketing and Market Access, Business Development and Licensing as well as Corporate Strategy and Financing.
In July 2022, Dr. Ho joined Medigene as CEO from Connect Biopharma (NASDAQ: CNTB) where he held the position of Chief Business Officer and, amongst other responsibilities, jointly led the execution of the company initial public offering (IPO) which closed in March 2021.
He also serves as an Executive-In-Residence at New Rhein Healthcare Investors, a venture capital and growth stage fund focused on healthcare therapeutics and medical devices and is a Non-Executive Director for Immodulon Therapeutics Ltd., a clinical stage company developing novel therapies for cancer based on bacterial derived immunomodulators.
Dr. Ho received his medical degree (MB BS) and Bachelor of Science (BSc) in Pharmacology from Imperial College, University of London, UK, and post-graduate qualifications (Dip Pharm Med) in Pharmaceutical Medicine from the Faculty of Pharmaceutical Physicians, Royal College of Physicians, UK.
Prof. Dr. Dolores J. Schendel
Since the 1970s, Prof. Dr. Dolores J. Schendel has been researching T cells and their abilities in immunotherapy and has accompanied the scientific and therapeutic turn of era in this field. Prof. Schendel served as a University Professor for Immunology at the Ludwig-Maximilians-University in Munich, is the author of more than 200 scientific publications and has spent several decades as a scientific review board member in various research organizations such as the German Research Foundation, German Cancer Aid and the European Research Council among others.
From 1998 – 2013, Prof Schendel was Director of the Institute of Molecular Immunology of the German Research Center for Environmental Health at the Helmholtz Center in Munich. Following this, she founded the Trianta Immunotherapies GmbH (today Medigene Immunotherapies GmbH). With the acquisition by Medigene in 2014, Medigene Immunotherapies GmbH was integrated into the Medigene Group and Prof. Schendel became Chief Scientific Officer (CSO) and, in 2016, also the CEO of the Group. With the new CEO joining in July 2022, she again focuses fully on her responsibilities as CSO and Head of Research and Development at Medigene as well as Managing Director of Medigene Immunotherapies GmbH.
Prof. Schendel completed her PhD in Genetics at the University of Wisconsin, USA, followed by post-doctoral training in immunology at University College London, UK. She developed her interest in tumor immunology while working at the Sloan-Kettering Institute for Cancer Research in New York. She is a recipient of the German Federal Order of Merit and the Bavarian Order of Merit and received the ‘Deutsche Krebshilfe Preis’, the award of the German Cancer Aid.